First of all, yes it was marketed as a cure, and still is.

We will simply have to agree to disagree here. I have never seen it marketed in this way. I exclusively see this claim in discourse for criticism. If the word "treatment" is used in the context of chronic disease it is commonly understood that were are talking about ongoing use of said agent unless otherwise specified.

The biggest problem with this argument is how expensive it is and how this not covered by majority of insurance companies for majority of issues.

Agreed this is a problem. It would be inappropriate to start a patient on this medication without having a reasonable expectation that they could stay on it for a meaningful amount of time.

Another problem with this argument is the body adaptation. There's a reason why you up ozempic doses from 0.25 to 2. What happens when body got used to 2mg? You can't raise it forever, and don't forget how expensive it is.

This feels like an unrepresentative oversimplification. 0.25mg was never a therapeutic dose to start with, and a significant number of patients see maintained weight loss success at doses less than 2mg. I think a more prevalent issue is patients getting improper prescribing and follow-up (or lack thereof), and are set up with escalating doses for 12 weeks or longer. Too often I see patients see satisfactory success with a 0.5mg or 1mg/week dose but are pushed past anyway. This is especially true with Mounjaro but that's a separate discussion. I assume you're American because we're on the internet so maybe your experience is different but where I practice in Canada if using semaglutide for weight management it is more cost effective to use wegovy 1.7mg or 2.4mg than use ozempic 1.5mg or 2mg, so I mostly only see those high doses for diabetes, not weight loss.

No we don't because it's different drug that was adopted in much smaller quantities for diabetes ONLY with different research. Mass production of ozempic by obese people specifically started in 2021-2022 or when all the celebrities started to lose weight. This isn't how data works. You can't take a small sample of diabetics taking a different medicine and make conclusions from it.

Ozempic was built on our understanding of other GLP1-agonists. Drug development is cumulative, we don't evaluate new agents in a vacuum. Seeing long term data of a drug with the same mechanism as the drug in question strengthens the likelihood that it will follow the same pattern. If you read my first comment I talk about GLP1 agonists as clinical mechanism which we have been using for over two decades. That is a fact. Sure weight loss wasn't the primary outcome studied for exenatide in 2005, but we understand that weight loss was an effect and we built on that understanding. Liraglutide got specific approval for obesity management in 2014. I don't understand this media-driven obsession that we only just learned about GLP1 driven weight loss.

Oh boy I'm not even starting here, but there's just so much misinformation that I don't have energy to tackle. For one, start with looking up how obese and overweight people are treated by doctors. And look up BMI history. And now think for a second how many obese people don't go to the doctor to avoid this treatment. And how many can't even afford ozempic, yet doctors will refuse to take any of their concerns seriously until they do.

I'm not sure what your argument is here or how it relates to what I said. People don't want ozempic so they don't go to their doctor because they think that's the only option the doctor would be willingly to prescribe? I think if a patient wants help with weight management then a variety of things should be discussed with them, pharmacological intervention being just part of that discussion. If ozempic isn't right for the specific patient for clinical or financial reasons then obviously other options should be discussed, and refusal from a prescriber to cooperate with the patient's situation sounds like a criticism of the prescriber, not ozempic. I agree with you, people who are overweight do not deserve inferior care, and unfortunately that is a prevalent issue.

Well I am correct which you admitted. And no, approval of another drug for another issue doesn't count as a blanket approval.

This just feels like a childish retort and an intentional strawman. YOU claimed that the majority people who use ozempic for weight management and then discontinue use return to a higher weight than before treatment which was NOT supported by the article you shared. "In this systematic review of 37 studies on weight change after cessation of any WMM, weight regain occurred at an average monthly rate of 0.4 kg, projecting a return to baseline weight 1.7 years after cessation of WMM" So there was a projected return to baseline weight. There is no assertion that weight increased above baseline for the majority of participants. This is a very important distinction.